303 related articles for article (PubMed ID: 25160598)
1. New treatments for diabetic retinopathy.
Das A; Stroud S; Mehta A; Rangasamy S
Diabetes Obes Metab; 2015 Mar; 17(3):219-30. PubMed ID: 25160598
[TBL] [Abstract][Full Text] [Related]
2. Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Zhang C; Wang H; Nie J; Wang F
Discov Med; 2014 Sep; 18(98):105-12. PubMed ID: 25227751
[TBL] [Abstract][Full Text] [Related]
3. TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes.
Jiang F; Chen Q; Huang L; Wang Y; Zhang Z; Meng X; Liu Y; Mao C; Zheng F; Zhang J; Yan H
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27120595
[TBL] [Abstract][Full Text] [Related]
4. Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
Das A; McGuire PG; Monickaraj F
Indian J Ophthalmol; 2016 Jan; 64(1):4-13. PubMed ID: 26953018
[TBL] [Abstract][Full Text] [Related]
5. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.
Murata T; Nakagawa K; Khalil A; Ishibashi T; Inomata H; Sueishi K
Lab Invest; 1996 Apr; 74(4):819-25. PubMed ID: 8606491
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW
Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803
[TBL] [Abstract][Full Text] [Related]
7. Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies.
Lupo G; Motta C; Giurdanella G; Anfuso CD; Alberghina M; Drago F; Salomone S; Bucolo C
Biochem Pharmacol; 2013 Dec; 86(11):1603-13. PubMed ID: 24076420
[TBL] [Abstract][Full Text] [Related]
8. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Wang JH; Ling D; Tu L; van Wijngaarden P; Dusting GJ; Liu GS
Pharmacol Ther; 2017 May; 173():1-18. PubMed ID: 28132907
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Matsui S; Kurimoto M; Kiryu J; Kita M; Suzuma I; Ohashi H; Ojima T; Murakami T; Kobayashi T; Masuda S; Nagao M; Yoshimura N; Takagi H
N Engl J Med; 2005 Aug; 353(8):782-92. PubMed ID: 16120858
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological approach to diabetic retinopathy.
De La Cruz JP; González-Correa JA; Guerrero A; de la Cuesta FS
Diabetes Metab Res Rev; 2004; 20(2):91-113. PubMed ID: 15037985
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy.
Felinski EA; Antonetti DA
Curr Eye Res; 2005 Nov; 30(11):949-57. PubMed ID: 16282129
[TBL] [Abstract][Full Text] [Related]
13. Insulin analogues may accelerate progression of diabetic retinopathy after impairment of inner blood-retinal barrier.
Kaya A; Kar T; Aksoy Y; Özalper V; Başbuğ B
Med Hypotheses; 2013 Dec; 81(6):1012-4. PubMed ID: 24090664
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response.
Cui B; Sun JH; Xiang FF; Liu L; Li WJ
Exp Eye Res; 2012 May; 98():37-43. PubMed ID: 22449442
[TBL] [Abstract][Full Text] [Related]
15. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
16. Suppression of protein kinase C-ζ attenuates vascular leakage via prevention of tight junction protein decrease in diabetic retinopathy.
Song HB; Jun HO; Kim JH; Yu YS; Kim KW; Kim JH
Biochem Biophys Res Commun; 2014 Jan; 444(1):63-8. PubMed ID: 24434146
[TBL] [Abstract][Full Text] [Related]
17. Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy.
Marek N; Raczyńska K; Siebert J; Myśliwiec M; Zorena K; Myśliwska J; Reiwer-Gostomska M; Trzonkowski P
Microvasc Res; 2011 Jul; 82(1):1-5. PubMed ID: 21539846
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of vascular permeability in diabetic retinopathy.
Antonetti DA; Lieth E; Barber AJ; Gardner TW
Semin Ophthalmol; 1999 Dec; 14(4):240-8. PubMed ID: 10758225
[TBL] [Abstract][Full Text] [Related]
19. Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy.
Alvarez Y; Chen K; Reynolds AL; Waghorne N; O'Connor JJ; Kennedy BN
Dis Model Mech; 2010; 3(3-4):236-45. PubMed ID: 20142328
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Kusari J; Zhou SX; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
